Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
September 17, 2021 09:00 ET | Celsion CORP
 Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform
September 02, 2021 08:00 ET | Celsion CORP
Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery...
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 08:00 ET | Celsion CORP
Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12,...
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
August 05, 2021 08:00 ET | Celsion CORP
LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
July 29, 2021 10:00 ET | Celsion CORP
Data show dose-dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response...
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
July 19, 2021 08:00 ET | Celsion CORP
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
July 15, 2021 08:00 ET | Celsion CORP
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 ...
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
July 01, 2021 08:00 ET | Celsion CORP
LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company,...
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
June 23, 2021 08:00 ET | Celsion CORP
Celsion GmbH will manage current and future cancer studies with ThermoDox® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J., June 23, 2021 ...
Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank
June 21, 2021 08:00 ET | Celsion CORP
Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J., June 21, 2021 (GLOBE...